We used PCNA as a proliferation marker, and through both immunoblotting and IHC, we observed a significant 43% reduction in thymic lymphoma proliferation in Tp53−/−; Prl2−/− mice compared with Tp53−/− controls (Fig. 4A–C). Here, TP53 is linked to thymus lymphoma.